Daniel Speidel
Company: Breakpoint Therapeutics
Job title: Co-Managing Director
Bio:
I am a biomedical scientist with 18 years experience in experimental cancer research and molecular oncology. Currently, I am the Co-Managing Director of Breakpoint Therapeutics GmbH, a new spin-off company of Evotec dedicated to the discovery of anti-cancer drugs that target the DNA Damage Response in cancer cells.
Since the beginning of my research career my interests have focused on (1) understanding cellular DNA damage responses at the molecular and genetic level, (2) the discovery of molecular drug targets, and (3) the identification and validation of new biomarkers that can predict the success of cancer therapy.
Before joining Breakpoint Therapeutics I worked at Evotec with the main aim to facilitate formation of a spin-out company in the area of DNA Damage Responses.
A former management consultant with McKinsey & Company, I have also advised several research-related organisations and other institutions on matters of strategic importance and helped my clients grow, change and further develop their unique, individual strengths.
I am a strong communicator and have served on many high-profile boards and committees, including research institute governing boards, grant review and selection panels, conference organising committees, editorial boards of international scientific journals, and the advisory boards of research and music organisations.
Seminars:
Panel Discussion: The Promise of ATR & Other Emerging DDR Targets 2:30 pm
day: Day One